Abbott gets a portfolio of 1,000 new drugs and expects to see its sales in the Latin American market double with its $3 billion buyout out of Chile's CFR Pharmaceutical.
Biosensors International unveiled its innovative bare-metal cobalt chromium system months after rumors of a takeover.
China's WuXi PharmaTech has completed work on a biologics safety testing facility in Suzhou, adding 38,000 square feet of lab space to its sprawling presence in the area.
Pharma industry probes are far from over, China-based professionals say. And with the country trying desperately to drive down healthcare costs for its population of close to 1.4 billion, Big Pharma had best be careful. Local officials are making it clear that Big Brother is watching.
More accusations against GlaxoSmithKline are flying in China, but this time they're not about bribery. They're about taxes. A government-run legal newspaper alleges that the British drug giant evaded millions in taxes, compounding the company's growing problems in the country.
Chinese CRO WuXi PharmaTech notched another strong sales quarter, boosting its revenue by 11.3% thanks to escalating demand for its manufacturing services.
"Ethics matter" in China--and it's time for multinationals to take note, according to the country's official news agency. With a reputation-tarnishing scandal, dented China sales and a former top exec facing up to a lifetime in prison, GlaxoSmithKline's tale should serve as a prime example of what can happen if they don't.
A Haitian orphan born without fingers on both hands became the first beneficiary of a 3-D printed prosthesis in that country last month. Britain's John Marshall and South Africa's Richard van As developed the prosthesis. The printing cost was only $300.
What lies ahead for GlaxoSmithKline in China? The company has been waiting to find out since last summer, when investigators there charged it in a massive bribery scheme. But Glaxo may finally get some answers Wednesday, when Chinese police will brief the media about the drugmaker.
Eli Lilly in 2003 sold an antibiotics manufacturing plant in Cosmopolis, Brazil, to Italy's ACS Dobfar. But the fact that it has been more than a decade since Eli Lilly owned the facility has not kept the company from being ordered to pay $450 million to cover medical costs of dozens of plant employees for health problems they said came from exposure to hazardous materials.